The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial
| Autor: | G. Mørk, J. Funk, C. Lützow-Holm, K.T. Smerud, H. Hønnås, Birgitta Meding, K. Wirén, N. Meland, M. Lodén |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry medicine.medical_treatment Dermatology medicine.disease Betamethasone valerate Double blind Clinical trial chemistry.chemical_compound Infectious Diseases Maintenance therapy chemistry Quality of life Hand eczema medicine Corticosteroid Moisturizer skin and connective tissue diseases business |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology. 26:597-601 |
| ISSN: | 0926-9959 |
| DOI: | 10.1111/j.1468-3083.2011.04128.x |
| Popis: | Background Hand eczema is a common and persistent disease with a relapsing course. Clinical data suggest thatonce daily treatment with corticosteroids is just as effective as twice daily treatment.Objectives The aim of this study was to compare once and twice daily applications of a strong corticosteroidcream in addition to maintenance therapy with a moisturizer in patients with a recent relapse of hand eczema.Methods The study was a parallel, double-blind, randomized, clinical trial on 44 patients. Twice daily application ofa strong corticosteroid cream (betamethasone valerate 0.1%) was compared with once daily application, where aurea-containing moisturizer was substituted for the corticosteroid cream in the morning. The investigator scored thepresence of eczema and the patients judged the health-related quality of life (HRQoL) using the Dermatology LifeQuality Index (DLQI), which measures how much the patient’s skin problem has affected his⁄her life over the pastweek. The patients also judged the severity of their eczema daily on a visual analogue scale.Results Both groups improved in terms of eczema and DLQI. However, the clinical scoring demonstrated thatonce daily application of corticosteroid was superior to twice daily application in diminishing eczema, especially inthe group of patients with lower eczema scores at inclusion.Conclusions Twice daily use of corticosteroids was not superior to once daily use in treating eczema. On thecontrary, the clinical assessment showed a larger benefit from once daily treatment compared with twice daily,especially in the group of patients with a moderate eczema at inclusion.Received: 11 February 2011; Accepted: 2 May 2011 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text